Neuroleptic malignant syndrome (NMS) is a rare, but fatal condition characterized by rigidity, fever, dysautonomia and altered consciousness along with elevated serum creatinine phosphokinase levels and leukocytosis. Treatment of NMS includes symptomatic and specific treatment with drugs like bromocriptine may be given. Risk factors for NMS include dehydration, parenteral antipsychotics and high potency antipsychotics. One of the important, but lesser known risk factors for NMS is low serum iron. Pronounced reduction in serum iron suggests that acute phase reactants do have a role in NMS. The present case report focuses on the importance of low serum iron as a risk factor for NMS.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137635PMC
http://dx.doi.org/10.4103/2229-516X.136800DOI Listing

Publication Analysis

Top Keywords

serum iron
16
low serum
12
iron risk
8
risk factor
8
neuroleptic malignant
8
malignant syndrome
8
risk factors
8
factors nms
8
nms
6
iron
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!